Learn / 25 Aug 2026

Zimmer Biomet Holdings (NYSE: ZBH): Shariah Screening & ESG Profile

As a global leader in medical technology, orthopedic reconstructive products, and surgical robotics, Zimmer Biomet Holdings, Inc. (NYSE: ZBH) offers a critical case study in balancing socially beneficial healthcare operations with conventional corporate debt structures and institutional ESG performance benchmarks.

Sector Screening

1. Core Business Activity & Permissibility

Zimmer Biomet designs, manufactures, and markets orthopedic implants, joint reconstruction systems, surgical robotics (ROSA), and digital health technologies:

Status: Permissible

Medical Devices & Healthcare

Developing joint implants, surgical instruments, and trauma systems serves real human needs (Hifz al-Nafs) and is a fully permissible (Halal) core commercial enterprise.

Purification Area

Treasury & Financial Income

Incidental income from cash holdings, international currency hedging, and bank interest requires ongoing monitoring and dividend purification where applicable.

Quantitative Screen

2. AAOIFI Financial Ratio Compliance (ZBH)

Financial leverage and liquidity ratios are evaluated against the strict 30% ceiling defined by AAOIFI Shariah Standard No. 21:

Screening Metric	AAOIFI Standard Limit	Zimmer Biomet Status	Compliance Verdict
Interest-Bearing Debt / Market Cap	< 30.00%	Long-term corporate bonds and term notes frequently push leverage above the 30% threshold depending on valuation cycles.	Non-Compliant / Volatile
Interest-Bearing Cash / Market Cap	< 30.00%	Cash, bank deposits, and short-term liquid investments remain safely below the 30% limit.	Compliant
Illiquid Assets / Total Assets	≥ 30.00%	Strong physical backing via manufacturing plants, clinical equipment, medical inventory, and IP assets.	Compliant
Non-Permissible Revenue Ratio	< 5.00%	Impermissible non-operating revenue accounts for less than 1% of total gross sales.	Compliant

ESG Scorecard

3. Environmental, Social, and Governance (ESG) Audit

Operating in the highly regulated MedTech sector, Zimmer Biomet focuses its ESG strategy on product quality, clinical safety, ethical marketing, and medical waste management:

Environmental (E) A • Moderate

Eco-Design & Waste Reduction

Programs targeting sustainable medical device packaging, reduction of hazardous chemical outputs, and Scope 1-2 energy efficiency initiatives across global plants.

Social (S) AA • Strong

Patient Safety & Product Quality

Strict clinical trial governance, rigorous FDA/MDR regulatory compliance, robust post-market surveillance, and health equity access initiatives.

Governance (G) AA • Strong

Compliance & Anti-Corruption

Comprehensive global anti-bribery policies for healthcare provider engagements, independent board oversight, and transparent recall protocols.

Executive Summary

4. Screening Verdict & Portfolio Takeaways

⚠️

          Overall Verdict: Shariah Screen Fail (High Leverage) & Strong ESG Rating

          While Zimmer Biomet operates in an ethically sound medical device sector with strong ESG product safety standards, its conventional debt-to-market-cap ratio frequently breaches the AAOIFI 30% leverage cap, rendering it non-compliant for standard Islamic equity portfolios until debt de-leveraging occurs.

Disclaimer: This equity screening case study is prepared strictly for analytical and educational purposes based on AAOIFI Shariah standards and institutional ESG disclosure metrics. It does not constitute formal religious rulings (Fatwas) or financial investment advice.

Information only. Purindex does not recommend buying, selling or holding any security.